<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01382108</url>
  </required_header>
  <id_info>
    <org_study_id>P/374/11/CCLR</org_study_id>
    <nct_id>NCT01382108</nct_id>
  </id_info>
  <brief_title>Meibography and Tear Scan Using the Oculus Keratograph 4</brief_title>
  <acronym>KITCHENER</acronym>
  <official_title>Meibography and Tear Scan Using the Oculus Keratograph 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Waterloo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Waterloo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at both the meibomian glands and the tear film using a
      new clinical instrument marketed in Canada which was recently acquired by the Centre for
      Contact Lens Research. These will be compared between two groups of individuals, one group
      with visible meibomian gland dysfunction (MGD) and one group of individuals with normal
      meibomian gland appearance. The hypothesis is that there will be a difference between normal
      individuals and individuals with MGD with respect to the appearance of the meibomian glands
      and certain tear film attributes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Meibomian gland dysfunction (MGD) is a common clinical condition and a major cause of
      evaporative dry eye with associated discomfort, visual disturbance and contact lens
      intolerance. In MGD, meibum is often abnormal, progressively changing in color from clear to
      yellow and in consistency from liquid to thick and toothpaste-like. Evaluation of the
      meibomian glands (MG) and lipid layer is vital. In a typical clinical setting, lid and lid
      margin evaluation is often performed via slitlamp biomicroscopy; however, the structure of
      the meibomian glands is often not clearly visualized when a slit lamp is used in isolation.
      Trans-illumination of the lids is necessary to clearly view these glands.

      To date, infrared meibography has been the only method available for the assessment of
      meibomian gland structure. It is primarily regarded as a laboratory-specific procedure for
      meibomian gland drop out assessment in people suffering from MGD. Recently, the Keratograph 4
      was released by OCULUS (Wetzlar, Germany). In addition to corneal and contact lens assessment
      features, the Keratograph 4 offers a tear film (TF) scan module able to objectively assess
      tear break-up time (TBUT) with a colour coded map highlighting the regions of tear break up.
      High-resolution images of tear meniscus can also be obtained and used for subjective
      assessment of tear meniscus height (TMH) with the help of built-in software. Preliminary
      research at the Centre for Contact Lens Research has demonstrated its ability to capture
      meibography images of the upper and lower lids.

      The objectives of this study are to collect meibography, TBUT and TMH data using the
      Keratograph 4 in normal participants (no MGD) and participants with MGD and to compare these
      between the two groups and before and after the use of a meibomian gland evaluator. The
      primary outcome variables are meibography images, TBUT and TMH.

      The study hypothesis is that here will be a difference between normal participants and
      participants with MGD, with respect to meibography images (MG drop out), TBUT measurements
      (area and time of break up) and TMH measurements.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Meibomium Gland Dropout Score - Evidence of Meibomian Gland Dysfunction (MGD) Confirmed by Meibograhpy Imaging Using the Keratograph 4 Measured on a Subjective Grading Scale (0-3) (Summing the Score for the Upper and Lower Lids for a Final Scale of 0-6)</measure>
    <time_frame>Before and after the use of a meibomian gland evaluator. Assessments will be separated by a period of at least 10 minutes.</time_frame>
    <description>Assessments will be made in normal participants (no MGD) and participants with MGD and compared between the two groups at baseline and after the use of a meibomian gland evaluator.
The meibomium gland dropout score subjective grading scale:
0 = no loss of mebomium glands
= area of meibomium gland loss less than 33%
= area of meibomium gland loss between 33% and 67%
= area of meibomium gland loss more than 67%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear Breakup Time (TBUT). The Time Taken, in Seconds, for the Tear Film to Break up on the Surface of the Cornea.</measure>
    <time_frame>Before and after the use of a meibomian gland evaluator. Assessments will be separated by a period of at least 10 minutes.</time_frame>
    <description>Measurements will be made in normal participants (no MGD) and participants with MGD and compared between the two groups at baseline and after the use of a meibomian gland evaluator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear Meniscus Height (TMH). The Height of the Tear Film Meniscus at the Eyelid Margin.</measure>
    <time_frame>Before and after the use of a meibomian gland evaluator. Assessments will be separated by a period of at least 10 minutes.</time_frame>
    <description>Assessments will be made in normal participants (no MGD) and participants with MGD and compared between the two groups at baseline and after the use of a meibomian gland evaluator.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">39</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>Normal participants</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Meibomian Gland Dysfunction</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Non-contact lens wearers will be recruited using CCLR records and advertising approved by
        the UW Office of Research Ethics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is at least 17 years of age and has full legal capacity to volunteer

          -  Has read and signed an information consent letter

          -  Is willing and able to follow instructions and maintain the appointment schedule

          -  Has had an ocular examination in the last two years

          -  Clinical criteria defining non-dry eye (controls) for study inclusion (Group 1):

               1. Composite symptom score of ≤ 12 on the OSDI questionnaire

               2. Meibum secretion quality score of 0 (grade 0-3) at the central eight meibomian
                  glands of the lower lid, in both eyes. Secretion quality score (grade 0-3):

        Grade 0 = normal, clear oil expressed (i.e., cooking oil appearance) Grade 1= opaque,
        diffusely turbid, normal viscosity Grade 2 = opaque, increased viscosity Grade 3 =
        inspissated (i.e., toothpaste-like appearance) or no expressed material Clinical criteria
        defining MGD dry eye for study inclusion (Group 2):

          1. Composite symptom score of ≥ 13 on the OSDI questionnaire

          2. Meibum secretion quality score ≥ 1.0 (grade 0-3) at the central eight meibomian glands
             of the lower lid, in both eyes. Secretion quality score (grade 0-3):

        Grade 0 = normal, clear oil expressed (i.e., cooking oil appearance) Grade 1 = opaque,
        diffusely turbid, normal viscosity Grade 2 = opaque, increased viscosity Grade 3 =
        inspissated (i.e., toothpaste-like appearance) or no expressed material

        Exclusion Criteria:

          -  Is a current contact lens wearer

          -  Has any ocular disease

          -  Is using any topical medications that may affect ocular health

          -  Has known sensitivity to the diagnostic pharmaceuticals to be used in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lyndon Jones, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Waterloo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Contact Lens Research, University of Waterloo</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2L 3G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <results_first_submitted>June 18, 2013</results_first_submitted>
  <results_first_submitted_qc>October 31, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2013</results_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Waterloo</investigator_affiliation>
    <investigator_full_name>Centre for Contact Lens Research</investigator_full_name>
    <investigator_title>Lyndon Jones, PhD</investigator_title>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>39 non-contact lens wearers were recruited using CCLR records</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Normal Participants</title>
          <description>Participants without Meibomian Gland Dysfunction</description>
        </group>
        <group group_id="P2">
          <title>Meibomian Gland Dysfunction</title>
          <description>Participants with Meibomian Gland Dysfunction</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normal Participants</title>
          <description>Participants without meibomian gland dysfunction</description>
        </group>
        <group group_id="B2">
          <title>Meibomian Gland Dysfunction</title>
          <description>Participants with Meibomian Gland Dysfunction</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.3" spread="6.1"/>
                    <measurement group_id="B2" value="59.5" spread="10.8"/>
                    <measurement group_id="B3" value="58.4" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Meibomium Gland Dropout Score - Evidence of Meibomian Gland Dysfunction (MGD) Confirmed by Meibograhpy Imaging Using the Keratograph 4 Measured on a Subjective Grading Scale (0-3) (Summing the Score for the Upper and Lower Lids for a Final Scale of 0-6)</title>
        <description>Assessments will be made in normal participants (no MGD) and participants with MGD and compared between the two groups at baseline and after the use of a meibomian gland evaluator.
The meibomium gland dropout score subjective grading scale:
0 = no loss of mebomium glands
= area of meibomium gland loss less than 33%
= area of meibomium gland loss between 33% and 67%
= area of meibomium gland loss more than 67%.</description>
        <time_frame>Before and after the use of a meibomian gland evaluator. Assessments will be separated by a period of at least 10 minutes.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Participants</title>
            <description>Participants without Meibomian Gland Dysfunction</description>
          </group>
          <group group_id="O2">
            <title>Meibomian Gland Dysfunction</title>
            <description>Participants with Meibomian Gland Dysfunction</description>
          </group>
        </group_list>
        <measure>
          <title>Meibomium Gland Dropout Score - Evidence of Meibomian Gland Dysfunction (MGD) Confirmed by Meibograhpy Imaging Using the Keratograph 4 Measured on a Subjective Grading Scale (0-3) (Summing the Score for the Upper and Lower Lids for a Final Scale of 0-6)</title>
          <description>Assessments will be made in normal participants (no MGD) and participants with MGD and compared between the two groups at baseline and after the use of a meibomian gland evaluator.
The meibomium gland dropout score subjective grading scale:
0 = no loss of mebomium glands
= area of meibomium gland loss less than 33%
= area of meibomium gland loss between 33% and 67%
= area of meibomium gland loss more than 67%.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjective grading (0-6) (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.0"/>
                    <measurement group_id="O2" value="3.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjective grading (0-6) (after 10 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.0"/>
                    <measurement group_id="O2" value="3.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tear Breakup Time (TBUT). The Time Taken, in Seconds, for the Tear Film to Break up on the Surface of the Cornea.</title>
        <description>Measurements will be made in normal participants (no MGD) and participants with MGD and compared between the two groups at baseline and after the use of a meibomian gland evaluator.</description>
        <time_frame>Before and after the use of a meibomian gland evaluator. Assessments will be separated by a period of at least 10 minutes.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Participants</title>
            <description>Participants without meibomian gland dysfunction</description>
          </group>
          <group group_id="O2">
            <title>Meibomian Gland Dysfunction</title>
            <description>Participants with Meibomian Gland Dysfunction</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Breakup Time (TBUT). The Time Taken, in Seconds, for the Tear Film to Break up on the Surface of the Cornea.</title>
          <description>Measurements will be made in normal participants (no MGD) and participants with MGD and compared between the two groups at baseline and after the use of a meibomian gland evaluator.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TBUT (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="6.6"/>
                    <measurement group_id="O2" value="6.7" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TBUT (after 10 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="6.1"/>
                    <measurement group_id="O2" value="7.6" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tear Meniscus Height (TMH). The Height of the Tear Film Meniscus at the Eyelid Margin.</title>
        <description>Assessments will be made in normal participants (no MGD) and participants with MGD and compared between the two groups at baseline and after the use of a meibomian gland evaluator.</description>
        <time_frame>Before and after the use of a meibomian gland evaluator. Assessments will be separated by a period of at least 10 minutes.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Participants</title>
            <description>Participants without meibomian gland dysfunction</description>
          </group>
          <group group_id="O2">
            <title>Meibomian Gland Dysfunction</title>
            <description>Participants with Meibomian Gland Dysfunction</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Meniscus Height (TMH). The Height of the Tear Film Meniscus at the Eyelid Margin.</title>
          <description>Assessments will be made in normal participants (no MGD) and participants with MGD and compared between the two groups at baseline and after the use of a meibomian gland evaluator.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TMH (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.1"/>
                    <measurement group_id="O2" value="0.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TMH (after 10 minutes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.1"/>
                    <measurement group_id="O2" value="0.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Normal Participants</title>
          <description>Participants without meibomian gland dysfunction</description>
        </group>
        <group group_id="E2">
          <title>Meibomian Gland Dysfunction</title>
          <description>Participants with Meibomian Gland Dysfunction</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathy Dumbleton</name_or_title>
      <organization>Centre for Contact Lens Research</organization>
      <phone>519-888-4567 ext 32694</phone>
      <email>kdumble@uwaterloo.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

